Wutzler P, De Clercq E, Wutke K, Färber I
Institute for Antiviral Chemotherapy, Friedrich-Schiller University of Jena, Germany.
J Med Virol. 1995 Jul;46(3):252-7. doi: 10.1002/jmv.1890460315.
The efficacy of oral brivudin vs. intravenous acyclovir was compared in a randomized multicentered study under double-blind conditions using the double-dummy technique. Forty-eight patients with a herpes zoster rash less than 72 hours in duration were entered in the study. Brivudin was given as one 125-mg tablet every 6 hours. Acyclovir was infused over 1 hour at a dose of 10 mg/kg every 8 hours. Treatment was continued for 5 days. There was no significant difference between the treatment groups when analyzed in terms of new lesion formation, increase in the area of rash within the primary dermatome, cutaneous dissemination, and affection of mucous membranes or visceral organs. Both treatment regimes were also equally effective in the time to full crusting of lesions. Oral brivudin and intravenous acyclovir were well tolerated by most patients. There was no need to interrupt the treatment in any case. As effective as intravenous acyclovir in the treatment of herpes zoster, oral brivudin offers the potential for outpatient treatment of herpes zoster in immunocompromised patients.
在一项采用双盲条件和双模拟技术的随机多中心研究中，对口服溴夫定与静脉注射阿昔洛韦的疗效进行了比较。48例带状疱疹皮疹持续时间少于72小时的患者进入该研究。溴夫定每6小时服用1片125毫克片剂。阿昔洛韦以10毫克/千克的剂量每8小时静脉输注1小时。治疗持续5天。在分析新皮损形成、原发性皮节内皮疹面积增加、皮肤播散以及黏膜或内脏器官受累情况时，各治疗组之间无显著差异。两种治疗方案在皮损完全结痂时间方面同样有效。大多数患者对口服溴夫定和静脉注射阿昔洛韦耐受性良好。在任何情况下都无需中断治疗。口服溴夫定在治疗带状疱疹方面与静脉注射阿昔洛韦一样有效，为免疫功能低下患者门诊治疗带状疱疹提供了可能。
